Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Rebastinib - Deciphera Pharmaceuticals

Next Previous
Search
Drug Profile

Rebastinib - Deciphera Pharmaceuticals

Alternative Names: DCC-2036; DP-1919; DP-1919.TO

Latest Information Update: 14 Jun 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Deciphera Pharmaceuticals
  • Developer Albert Einstein College of Medicine; Deciphera Pharmaceuticals
  • Class Amides; Antineoplastics; Fluorobenzenes; Pyrazoles; Pyridines; Quinolines; Small molecules; Urea compounds
  • Mechanism of Action Bcr-Abl tyrosine kinase inhibitors; Fms-like tyrosine kinase 3 inhibitors; Lyn protein-tyrosine kinase inhibitors; Proto-oncogene protein c-hck inhibitors; TIE-2 receptor antagonists; TrkA receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Acute myeloid leukaemia; Breast cancer; Chronic myeloid leukaemia; Endometrial cancer; Ovarian cancer; Precursor cell lymphoblastic leukaemia-lymphoma; Solid tumours

Most Recent Events

  • 11 Jun 2024 Deciphera Pharmaceuticals has been acquired by Ono Pharmaceutical
  • 01 Nov 2022 Deciphera Pharmaceuticals terminates a phase Ib/II trial for Solid tumours (Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA due to termination of development programme (PO) (NCT03717415)
  • 01 Nov 2022 Deciphera Pharmaceuticals completes a phase Ib/II trial for Solid tumours (Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (PO) (NCT03717415)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top